+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Cell Analysis, Instruments, Consumables and Reagents

  • ID: 4716278
  • Report
  • Region: Global
  • 235 Pages
  • BCC Research
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche Ag
  • Intellicyt Corp.
  • Merck Millipore
  • Qiagen Inc.
  • MORE
Report Scope:

The scope of this report is broad and covers product type, end users, techniques and applications of cancer cell analysis instruments and consumables. Revenue forecasts from 2018 through 2023 are given for each of the segments and regional markets with estimated values derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each region and explains the major drivers and regional dynamics of the global cancer cell analysis market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors.

The Report Includes:
  • 100 data tables and 91 additional tables
  • Detailed overview of the global market for cancer cell analysis in instruments, reagents and consumables
  • Analyses of the global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Qualitative and quantitative study of the cancer cell analysis industry by product type, end user, analyses technique, application
  • Assessment of the major drivers and regional dynamics of the global cancer cell analysis market and current trends within the industry
  • Emphasis on the vendor landscape and detailed profiles of the major vendors in the cancer cell analysis market, including Abbott Laboratories, Bio-Rad Laboratories Inc., GE Healthcare, Merck Millipore, QIAGEN Inc., Siemens Healthcare and ThermoFischer Scientific
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche Ag
  • Intellicyt Corp.
  • Merck Millipore
  • Qiagen Inc.
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst’s Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

  • Introduction
  • Current Technologies, Trends and Advancements
  • Industry Growth Drivers
  • Rising Incidences of Different Types of Cancers Across the Globe
  • Surging Investment for Cancer-Based Research
  • Growing Importance of Cell Assay-Based Drug Development
  • Increasing Demand for the Development of Personalized Medicine for Cancer
  • Advancements in Stem Cell Analysis and Biomarker Technology

Chapter 4 Market Breakdown by Technology Type

  • Consumables
  • Reagents
  • Assay Kits
  • Media
  • Microplates
  • Others (Beads and Blocking Sera)
  • Instruments
  • Cytometers
  • Spectrophotometer
  • Cell Counters
  • Cell Isolation and Separation Instruments
  • Microscopes
  • Cell Microarrays
  • Quantitative PCR
  • Others

Chapter 5 Market Breakdown by End User

  • Pharma and Biotech Companies
  • Increasing Cancer Prevalence: A Key Opportunity Provider
  • Cell Therapy
  • Contract Research Organizations (CROs)
  • Research and Academic Institutes
  • Basic Cancer Research
  • Translational Research
  • Clinical Research
  • Clinical Trials
  • Laboratories and Hospitals
  • Blood Chemistry Test
  • Complete Blood Count (CBC)
  • Cytogenetic Analysis
  • Immunophenotyping
  • Sputum Cytology
  • Tumor Marker Tests

Chapter 6 Market Breakdown by Technique

  • Molecular Approach
  • Polymerase Chain Reaction (PCR)
  • NGS (Next-Generation Sequencing)
  • Microfluidics
  • Others
  • Cell Imaging Approach
  • Fluorescent In Situ Hybridization (FISH)
  • Microscopy
  • High Content Screening
  • Rising Adoption and Development of Anti-Cancer Drugs
  • Cytometry
  • Others

Chapter 7 Market Breakdown by Application

  • Cell Imaging
  • Technological Advancements in Cell Imaging
  • Cell Viability and Proliferation
  • Cell Signaling Pathways
  • RNA Expression
  • Cell Growth and Manipulation
  • Cell Immunotherapy
  • Dendritic Cell (DC) Vaccine
  • Tumor-Infiltrating Lymphocytes (TIL) Therapy
  • T Cell Receptor (TCR) Therapy
  • Chimeric Antigen Receptor (CAR) T cell Therapy
  • Flow Cytometry
  • Genotypic or Phenotypic Research
  • Drug Discovery and Development

Chapter 8 Market Breakdown by Region

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
  • Europe
  • United Kingdom
  • France
  • Germany
  • Spain
  • Italy
  • Rest of Europe
  • ROW
  • Latin America
  • Middle East and Africa

Chapter 9 Industry Structure of Global Cancer Cell Analysis Market

  • Industry Structure and Supply Chain Analysis for Global Cancer Cell Analysis Market
  • R&D
  • Suppliers
  • Manufacturers
  • End Users
  • Investment Analysis and Future Growth Prospects

Chapter 10 Patent Analysis

  • U.S. Patent Analysis
  • European Patent Analysis
  • Japanese Patent Analysis

Chapter 11 Company Profiles

  • Abbott Laboratories
  • Acea Bioscience Inc.
  • Agilent Technologies Inc.
  • Becton, Dickinson And Co.
  • Bio-Rad Laboratories
  • Cellix Ltd.
  • Cynvenio Biosystems Inc.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ag
  • Fluidigm Corp.
  • GE Healthcare
  • Genscript
  • Intellicyt Corp.
  • Logos Biosystems
  • Lonza Group Ltd.
  • Lumacyte Llc
  • Merck Millipore
  • Olympus Corp.
  • Perkinelmer, Inc.
  • Promega Corp.
  • Qiagen Inc.
  • Siemens Healthcare Gmbh
  • Tecan Group Ltd.
  • Thermofischer Scientific
  • Takara Bio

List of Tables
Summary Table: Global Market for Cancer Cell Analysis, by Product Type, Through 2023
Table 1: Current Technologies Used in Cancer Cell Analysis
Table 2: Global Prevalence of Cancer, by Type, 2016
Table 3: Major Types of Cancer Prevalence, by Region, 2015 and 2016
Table 4: Investment in Cancer, by Areas of Research
Table 5: Investments in Cancer-Based Research
Table 6: Major Types of Cell-Based Assay Used in HTS for Drug Screening
Table 7: Products in Clinical Development and Regulatory Review, 2016
Table 8: Drugs in Pipeline for Selected Causes, 2017
Table 9: Specific Issues in Personalized Medicine and Cancer
Table 10: In Vivo Versus In Vitro Stem Cell Assays
Table 11: Biomarkers for Cancer Detection, Diagnosis and Prognosis
Table 12: Global Market for Cancer Cell Analysis, by Product Type, Through 2023
Table 13: Global Market Shares of the Cancer Cell Analysis, by Product Type, 2017 vs. 2023
Table 14: A Summary of Relevant Single-cell Methods and their Applications to Cancer
Table 15: Global Market for Cancer Cell Analysis, by Consumables, Through 2023
Table 16: Global Market for Consumables in Cancer Cell Analysis, by Region, Through 2023
Table 17: Global Market for Reagents, by Region, Through 2023
Table 18: Kits and Reagents for the Separation of CSCs from Various Starting Materials
Table 19: Kits and Reagents for the Separation of CTCs from Various Starting Materials
Table 20: Global Market for Assay Kits, by Region, Through 2023
Table 21: Determination of Apoptosis and Necrosis in Cancer Cells
Table 22: Summary of Intracellular Metabolic Assays Available to Measure Cellular Proliferation
Table 23: Global Market for Media, by Region, Through 2023
Table 24: The American Cancer Society’s Estimate for Lung Cancer in the United States, 2018
Table 25: Global Market for Microplates, by Region, Through 2023
Table 26: Medicines in Development for Cancer, 2018
Table 27: Global Market for Other Consumables, by Region, Through 2023
Table 28: Global Market for Cancer Cell Analysis, by Instruments, Through 2023
Table 29: Global Market for Cytometers in Cancer Cell Analysis, by Type, Through 2023
Table 30: Global Cytometer Market, by Region, Through 2023
Table 31: Estimated Female Breast Cancer Deaths in the U.S., by Age, 2017
Table 32: Global Spectrophotometers Market, by Region, Through 2023
Table 33: Global Market for Cell Counters in Cancer Cell Analysis, by Type, Through 2023
Table 34: Automatic Cell Counter Technology
Table 35: Comparison Between Manual Cell Counters and Automated Cell Counters
Table 36: Global Market for Cell Counters, by Region, Through 2023
Table 37: Characteristics of Cells
Table 38: Cell Isolation and Separation Techniques
Table 39: Global Market for Cell Isolation and Separation Instruments, by Region, Through 2023
Table 40: Global Market for Microscopes, by Region, Through 2023
Table 41: Global Market for Cell Microarrays, by Region, Through 2023
Table 42: Global Quantitative PCR Market, by Region, Through 2023
Table 43: Global Market for Other Instruments, by Region, Through 2023
Table 44: Global Market for Cancer Cell Analysis, by End User, Through 2023
Table 45: Prevalence of Cancer in Major Countries, by Type, 2015
Table 46: Ongoing Drug Developments and Trials for Cancer
Table 47: Deaths, by Cancer in Major Countries, 2015
Table 48: Global Market for Pharma and Biotech Companies, by Region, Through 2023
Table 49: Technology Approvals and Advancements, by Major Players
Table 50: CAR T-Cell Therapy in Immuno-Oncology Medicine Development, 2017
Table 51: Development Works Initiated in CAR T Therapy
Table 52: Global Market for Contract Research Organizations, by Region, Through 2023
Table 53: Market Share of for Drugs Under Development, 2016
Table 54: Some of the Major Collaborations
Table 55: Global Market for Research Organizations and Academic Institutes, by Region, Through 2023
Table 56: International Cancer Research Projects, by Region, 2017-2018
Table 57: Clinical Trials in the Field of Cancer Research
Table 58: Current Grants in the U.S., by Cancer Type, 2018
Table 59: Investment in Cancer Research in Canada, by Cancer Type
Table 60: Global Market for Laboratories and Hospitals, by Region, Through 2023
Table 61: Share of Population with Cancer, by Type, 2016
Table 62: Global Market for Cancer Cell Analysis, by Technique, Through 2023
Table 63: Global Market for Cancer Cell Analysis Techniques, by Region, Through 2023
Table 64: Global Market for Molecular Approach in Cancer Cell Analysis, by Application, Through 2023
Table 65: Global Market for Molecular Approaches in Cancer Cell Analysis, by Region, Through 2023
Table 66: Global Market for PCR in Cancer Cell Analysis, by Region, Through 2023
Table 67: Global Cancer Incidence, by Year, 2005-2016
Table 68: Global Market for Next-Generation Sequencing in Cancer Cell Analysis, by Region, Through 2023
Table 69: NGS Sequencers and Sequencing Technology
Table 70: Various Enrichment Technologies for NGS
Table 71: Quality Control (QC) Metrics for Next-Generation Sequencing
Table 72: Cancer Deaths Worldwide, 2006-2016
Table 73: Global Market for Microfluidics in Cancer Cell Analysis, by Region, Through 2023
Table 74: Size-Based Cancer Cell Separation Microfluidic Devices
Table 75: Microfluidics Devices for Cancer Cell Biophysical Property Characterization
Table 76: Global Market for Other Molecular Approaches in Cancer Cell Analysis, by Region, Through 2023
Table 77: Protein Arrays for the Cancer Biomarker Discovery
Table 78: Global Market for the Cell Imaging Approach in Cancer Cell Analysis, by Region, Through 2023
Table 79: Major Growth Drivers for Global Cell Imaging Approach Market
Table 80: Global Market for the Cell Imaging Approach in Cancer Cell Analysis, by Application, Through 2023
Table 81: Global Market for FISH in Cancer Cell Analysis, by Region, Through 2023
Table 82: Application of FISH for the Study of Different Cancer Types
Table 83: Global Market for Microscopy in Cancer Cell Analysis, by Region, Through 2023
Table 84: Clinical Trials in Microscopy
Table 85: Global Market for High Content Screening in Cancer Cell Analysis, by Region, Through 2023
Table 86: Initiatives for the Development of Anti-Cancer Drugs, 2016-2018
Table 87: Global Market for Cytometry in Cancer Cell Analysis, by Region, Through 2023
Table 88: Global Deaths Due to Leukemia, 2016
Table 89: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Table 90: Clinical Trials in Cytometry
Table 91: Global Market for Other Cell Imaging Approaches in Cancer Cell Analysis, by Region, Through 2023
Table 92: Global Deaths Due to Breast Cancer, 2012-2016
Table 93: Global Market for Cancer Cell Analysis, by Application, Through 2023
Table 94: Global Market for Cell Imaging Application, by Region, Through 2023
Table 95: Global Market for Cell Imaging in Cancer Cell Analysis, by Region, Through 2023
Table 96: Rising Prevalence of Cancer, by Type, 2005-2015
Table 97: Global Market for Cell Viability and Proliferation in Cancer Cell Analysis, by Region, Through 2023
Table 98: Cell Viability at Various Concentrations of Anti-Cancer Drug
Table 99: Global Market for Cell Signaling Pathways in Cancer Cell Analysis, by Region, Through 2023
Table 100: National Cancer Institute (NCI) Cancer Research Funding, by Cancer Type, 2014-2016
Table 101: Global Market for RNA Expression in Cancer Cell Analysis, by Region, Through 2023
Table 102: Ongoing and Completed Clinical Trials on RNA Expression-based Cancer Cell Analysis
Table 103: Biotechnology R&D Expenditures, by Country, 2011 and 2015
Table 104: Key Differences in Normal Cells and Cancer Cells
Table 105: Global Market for Cell Growth and Manipulation in Cancer Cell Analysis, by Region, Through 2023
Table 106: In Vitro and In Vivo Studies Deploying Modified and Altered Exosomes for Effective Cancer Treatment
Table 107: Global Market for Cell Immunotherapy in Cancer Cell Analysis, by Region, Through 2023
Table 108: Global Market for Flow Cytometry in Cancer Cell Analysis, by Region, Through 2023
Table 109: Global Market for Genotypic or Phenotypic Research in Cancer Cell Analysis, by Region, Through 2023
Table 110: Active Clinical Studies Involving Genotypic or Phenotypic Cancer Research, 2015-2018
Table 111: Global Market for Drug Discovery and Development in Cancer Cell Analysis, by Region, Through 2023
Table 112: North American Market for Cancer Cell Analysis, by Country, Through 2023
Table 113: U.S. Cancer Incidence in Males, by Cancer Type, 2017
Table 114: U.S. Cancer Incidence in Females, by Cancer Type, 2017
Table 115: Current Grants, by Cancer Type, 2017
Table 116: Estimates of National Expenditures for Cancer Care, by Cancer Site, 2010-2017
Table 117: Canadian Cancer Incidence in Males, by Cancer Type, 2017
Table 118: Canadian Cancer Incidence in Females, by Cancer Type, 2017
Table 119: Current Cancer Research Funding in Canada, 2018
Table 120: Asia-Pacific Market for Cancer Cell Analysis, by Country, Through 2023
Table 121: Cancer Prevalence Based on Incidence Rates, 2016
Table 122: Clinical Trials for Cancer Cell Analysis
Table 123: Commonly Diagnosed Cancers in Male, by Cancer Type, 2017
Table 124: Commonly Diagnosed Cancers in Female, by Cancer Type, 2017
Table 125: Percentage Change in Cancer Prevalence, 2005-2016
Table 126: Distribution, by Cancer Type, 2015
Table 127: Clinical Trials for Cancer Cell Analysis (Singapore)
Table 128: European Cancer Cell Analysis Market, by Country, Through 2023
Table 129: Estimated Number of People Living with Cancer in the U.K., by Country, 2015 and 2020
Table 130: Site-specific Research Funding in the United Kingdom, 2015
Table 131: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2015
Table 132: Ongoing and Completed Clinical Trials on Cancer Cell Analysis in France
Table 133: Estimates of Spain’s Cancer Incidence in Men and Women, by Cancer Type, 2015
Table 134: DFF-Research Projects Grants from the Danish Council for Independent Research to Promote Cancer Cell Analysis in June 2015
Table 135: Projects Recommended to the NCU Board for Funding, 2016
Table 136: ROW Cancer Cell Analysis Market, by Country, Through 2023
Table 137: Brazil’s New Cases of Cancer, by Gender, 2016
Table 138: Clinical Trials in Mexico for Cancer Cell Analysis
Table 139: Leading Causes of Death in Argentina and Percentage Change from 2005 to 2016
Table 140: Kenya’s Prevalence of Cancer, by Cancer Type, 2015 and 2016
Table 141: M&A Deals in Life Science Sector, 2017
Table 142: Investment Analysis
Table 143: U.S. Cancer Cell Analysis Patent, 2018
Table 144: European Cancer Cell Analysis Patents, 2015-2018
Table 145: Japanese Cancer Cell Analysis Patent, 2015-2018
Table 146: Abbott: Product Portfolio
Table 147: Abbott: Recent Developments, 2018
Table 148: ACEA Biosciences Inc.: Product Portfolio
Table 149: ACEA Biosciences Inc.: Recent Developments, 2017 and 2018
Table 150: Agilent Technology Inc.: Product Portfolio
Table 151: Agilent Technology Inc.: Recent Developments, 2015-2017
Table 152: Becton, Dickinson and Co.: Product Portfolio
Table 153: Becton, Dickinson and Co.: Recent Developments, 2015-2018
Table 154: Bio-Rad Laboratories Inc.: Product Portfolio
Table 155: Bio-Rad Laboratories Inc.: Recent Developments, 2016 and 2017
Table 156: Cellix Ltd.: Product Portfolio
Table 157: Cynvenio Biosystems Inc.: Product Portfolio
Table 158: Cynvenio Biosystems Inc.: Recent Developments, 2017 and 2018
Table 159: Danaher Corp.: Product Portfolio
Table 160: Danaher Corp.: Recent Developments, 2016-2018
Table 161: F. Hoffmann-LA Roche AG: Product Portfolio
Table 162: F. Hoffmann-LA Roche AG: Recent Developments, 2015-2017
Table 163: Fluidigm Corp.: Product Portfolio
Table 164: Fluidigm Corp.: Recent Developments, 2018
Table 165: GE Healthcare: Product Portfolio
Table 166: GE Healthcare: Recent Developments, 2017 and 2018
Table 167: GenScript: Product Portfolio
Table 168: Intellicyt Corp.: Product Portfolio
Table 169: Intellicyt Corp.: Recent Developments, 2016-2018
Table 170: Logos Biosystems: Product Portfolio
Table 171: lonza Group Ltd.: Product Portfolio
Table 172: LumaCyte LLC: Product Portfolio
Table 173: LumaCyte LLC: Recent Developments, 2016-2018
Table 174: Merck Millipore: Product Portfolio
Table 175: Merck Millipore: Recent Developments, 2016-2018
Table 176: Olympus Corp.: Product Portfolio
Table 177: Olympus Corp.: Recent Developments, 2015-2018
Table 178: PerkinElmer Inc.: Product Portfolio
Table 179: PerkinElmer Inc.: Recent Developments, 2015-2018
Table 180: Promega Corp.: Product Portfolio
Table 181: QIAGEN Inc.: Product Portfolio
Table 182: QIAGEN Inc.: Recent Developments, 2015-2018
Table 183: Siemens Healthcare GmbH: Product Portfolio
Table 184: Siemens Healthcare GmbH: Recent Developments, 2016-2018
Table 185: Tecan Group Ltd.: Product Portfolio
Table 186: Tecan Group Ltd.: Recent Developments, 2015-2017
Table 187: ThermoFischer Scientific: Product Portfolio
Table 188: ThermoFischer Scientific: Recent Developments, 2017 and 2018
Table 189: Takara Bio: Product Portfolio
Table 190: Takara Bio: Recent Developments, 2017 and 2018

List of Figures
Summary Figure: Global Market for Cancer Cell Analysis, by Product Type, 2017-2023
Figure 1: Applications of Cancer Cell Analysis: A General Overview
Figure 2: Global Prevalence of Cancer, by Type, 2016
Figure 3: The Drug Discovery Process: The Assay Development Stage
Figure 4: Products in Clinical Development and Regulatory Review, 2016
Figure 5: Global Market Shares of the Cancer Cell Analysis, by Product Type, 2017 vs. 2023
Figure 6: Five Major Classes in In Vitro-Based Assays
Figure 7: Estimated New Cases of Leukemia, Lymphoma, and Myeloma, 2018
Figure 8: Basic Components of a Spectrophotometer
Figure 9: Classification of Cell Microarrays
Figure 10: Key Application of Quantitative PCR or Real-Time PCR
Figure 11: End-User Segmentation
Figure 12: Workflow for Gene Expression
Figure 13: Prevalence of Cancer in Major Countries, by Type, 2015
Figure 14: Deaths, by Cancer in Major Countries, 2015
Figure 15: CAR T Cell Therapy in Immuno-Oncology Medicine Development, 2017
Figure 16: CAR T Cell Therapy Mechanism
Figure 17: Private Risk Sharing Contracts Announced, 1990-2017
Figure 18: Market Share for the Drugs Under Development, 2016
Figure 19: Projects in Development Based on Novel Approaches, by Type, 2016
Figure 20: Primary Growth Drivers
Figure 21: Application of Single-Cell Analysis in Cancer Research
Figure 22: Prevalence of Prostate Cancer in the United States
Figure 23: Share of Population with Cancer, by Type, 2016
Figure 24: Workflow for Laboratories Undertaking Molecular Pathology for Cancer Patients from Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Samples
Figure 25: Clinical Use of Molecular Diagnostics
Figure 26: Global Cancer Incidence, by Year, 2005-2016
Figure 27: Cancer Deaths Worldwide, 2006-2016
Figure 28: Subsegments of Cell Imaging Approach
Figure 29: Advantages Offered by Fluorescent In Situ Hybridization
Figure 30: Types of Microscopy Techniques
Figure 31: Advantages Offered by High Content Screening
Figure 32: Global Deaths Due to Leukemia, 2016
Figure 33: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Figure 34: Global Deaths Due to Breast Cancer, 2012-2016
Figure 35: Applications of Cancer Cell Analysis
Figure 36: Types of Cancer Cell Imaging
Figure 37: Workflow for an Imaging-Based Cell Migration Experiment
Figure 38: Cell Viability at Various Concentrations of Anti-Cancer Drug
Figure 39: Mechanism of Cell Signaling
Figure 40: Types of Cell Signaling Pathways
Figure 41: National Cancer Institute (NCI) Cancer Research Funding, by Cancer Type, 2014-2016
Figure 42: Techniques of RNA Expression
Figure 43: Biotechnology R&D Expenditures, by Country, 2011 and 2015
Figure 44: Antitumor Impacts of Innate Immune Cells
Figure 45: Integration of Gene Therapy and Stem Cells for Cancer Treatment
Figure 46: Production Process of CAR T Cells
Figure 47: Flow Cytometry Automated Cancer Cell Analysis Pipeline
Figure 48: Application of Single-Cell Sequencing Technology in Tumor Evolution and Metastasis
Figure 49: Major Breakthroughs in Cancer Research in India
Figure 50: Commonly Diagnosed Cancers in Male, by Cancer Type, 2017
Figure 51: Commonly Diagnosed Cancers in Females, by Cancer Type, 2017
Figure 52: Distribution, by Cancer Type, 2015
Figure 53: Estimated Number of People Living with Cancer in the U.K., by Country, 2015 and 2020
Figure 54: Workflow of Anticancer Drug Discovery
Figure 55: Site-specific Research Funding in the United Kingdom, 2015
Figure 56: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2015
Figure 57: Estimates of Spain’s Cancer Incidence in Men and Women, by Cancer Type, 2015
Figure 58: Keyna’s Prevalence of Cancer, by Cancer Type, 2015 and 2016
Figure 59: Industry Process Flow within Cancer Cell Analysis Market
Figure 60: Outline of Cancer Cell Analysis Industry
Figure 61: R&D Phase from Conceptualization to Development
Figure 62: Marketing Matrix for Cancer Cell Analysis Products
Figure 63: Factors Influencing Contracts with Suppliers within the Cancer Cell Analysis Market
Figure 64: Factors Driving M&A Deals Across the Life Science Sector
Figure 65: Generalized Manufacturing Process Flow for Cancer Cell Analysis Products
Figure 66: Global Oncology Therapeutic and Care Spending, 2013-2020

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories
  • Acea Bioscience Inc.
  • Agilent Technologies Inc.
  • Becton, Dickinson And Co.
  • Bio-Rad Laboratories
  • Cellix Ltd.
  • Cynvenio Biosystems Inc.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ag
  • Fluidigm Corp.
  • GE Healthcare
  • Genscript
  • Intellicyt Corp.
  • Logos Biosystems
  • Lonza Group Ltd.
  • Lumacyte Llc
  • Merck Millipore
  • Olympus Corp.
  • Perkinelmer, Inc.
  • Promega Corp.
  • Qiagen Inc.
  • Siemens Healthcare Gmbh
  • Takara Bio
  • Tecan Group Ltd.
  • Thermofischer Scientific
Note: Product cover images may vary from those shown
Adroll
adroll